Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer

Nephrology (Carlton). 2020 Sep;25(9):730. doi: 10.1111/nep.13721. Epub 2020 May 20.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / pathology
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Biopsy / methods*
  • Erlotinib Hydrochloride* / administration & dosage
  • Erlotinib Hydrochloride* / adverse effects
  • Glucocorticoids / administration & dosage
  • Humans
  • Kidney Function Tests
  • Kidney* / drug effects
  • Kidney* / pathology
  • Kidney* / physiopathology
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Nephritis, Interstitial* / chemically induced
  • Nephritis, Interstitial* / diagnosis
  • Nephritis, Interstitial* / physiopathology
  • Nephritis, Interstitial* / therapy
  • Prednisolone / administration & dosage*
  • Recovery of Function
  • Withholding Treatment

Substances

  • Antineoplastic Agents
  • Glucocorticoids
  • Prednisolone
  • Erlotinib Hydrochloride